One of the most common mechanisms underlying immunotherapy is programmed cell-death protein-1 (PD-1) and programmed cell-death ligand-1 (PD-L1), which serve as immune checkpoints in the tumor microenvironment [7,8]. The gene discussed is CD274; the disease is neoplasm.